[E-Daily Starin Choi Hee-jae Reporter] The movie "Tazza: The Song of Beelzebub" continues its box office success, ranking second for three consecutive days since its release. Poster for the movie “Tazza: The Song of Beelzebub” (Photo courtesy of CJ ENM) According to the Korean Film Council’s integrated computer network, the movie “Tazza: The Song of Beelzebub” ranked second at the box office on the 25th—its third day in theaters—having drawn a cumulative audience of 448,235. According to distributor CJ ENM, “Tazza: The Song of Beelzebub” is demonstrating the power of word-of-mouth with advance ticket sales and seat occupancy rates that exceed pre-release projections based on advance booking rankings. As of the 26th, the CGV Golden Egg Index stands at 93%, up from the previous day. Even considering that this is the film’s opening week, this figure is higher than the 79% for the previous installment, “Tazza: The Hand of God,” and the 82% for “Tazza: One-Eyed Jack.” Despite its “No Minors Allowed” rating, “Tazza: The Song of Beelzebub” is driving box office success thanks to consistently positive audience reviews. With a high Golden Egg Index and steadily increasing advance ticket sales, all eyes are on whether the film will maintain its box office momentum through word of mouth during the Chuseok holiday. The final installment of the *Tazza* series, *Tazza: The Song of Beelzebub*, is a crime thriller in which Jang Tae-young (Byeon Yo-han)—who thought he had it all thanks to his online casino business—and his best friend of the same name, Park Tae-young (Noh Jae-won), who took everything from him, meet again on the global gambling scene to settle a score. The film stars Byun Yo-han and Noh Jae-won, along with Ayaka Miyoshi, Jo Woo-jin, Yoon Kyung-ho, Tsuyoshi Ihara, Hong Dao, Kim Min-ho, Im Se-mi, and Moon Ji-hoon (Swing).
An accounting illusion—where losses grow as stock prices rise—is clouding investors’ judgment. This is because the conversion value of previously issued convertible bonds (CBs) or bonds with warrants …
Mezzion Pharma Co., Ltd.(140410)has established an additional U.S. subsidiary dedicated exclusively to the development of treatments for autosomal dominant polycystic kidney disease (ADPKD).According …
Jin Yang-gon, Chairman of HLB INC., announced on the 24th via the company’s official YouTube channel that “Lirapugratinib” (RLY-4008), a treatment for bile duct cancer, had received approval from the …